The Use of Magnesium to Improve Blood Pressure, Cholesterol, and Glucose Control
- Conditions
- HypertensionDiabetesDyslipidemiaCoronary Artery Disease
- Registration Number
- NCT00282659
- Lead Sponsor
- Hartford Hospital
- Brief Summary
The purpose of this study is to determine if magnesium can improve blood pressure, cholesterol, and blood sugar control in patients with implantable cardioverter defibrillators (ICDs).
- Detailed Description
Magnesium is the second most abundant intracellular cation and plays a vital role in many physiologic processes. It has been determined that patients with cardiovascular disease have intracellular magnesium (Mgi) deficiencies. Among the ICD registries in Europe and the United States 64% and 77% of patients also carry the diagnosis of CAD, respectively. Patients with CAD have risk factors that lead to the development and or propagation of atherosclerosis. Paramount among these risk factors are hypertension, dyslipidemia, and diabetes.
Comparison: Magnesium compared to placebo in patients with ICDs to evaluate the effect they have on cholesterol, blood pressure, and blood glucose.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 240
- Newly implanted ICD or recent ICD shock (within 6 months)
- Inability to swallow
- A non-cardiac disease with a survival prognosis of less than 12 months
- Hypermagnesemia
- Creatinine clearance less than 30mL/min
- Lactic acidosis or systemic acidosis syndrome
- Previous intolerance to magnesium L-lactate
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Blood pressure, cardiac output, systemic vascular resistance, thoracic fluid content, total cholesterol, low density lipoprotein, high density lipoprotein, triglycerides, and blood glucose at baseline, 3, and 6 months of follow-up
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Hartford Hospital
🇺🇸Hartford, Connecticut, United States